Fibroblast Activation Protein–Directed Imaging Outperforms 18 F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.124.267473 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Lukas Kessler und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; lukas.kessler@uk-…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Mesothelioma, Endopeptidases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
The fibroblast activation protein (FAP) is highly expressed in tumor and stromal cells of mesothelioma and thus is an interesting imaging and therapeutic target. Previous data on PET imaging with radiolabeled FAP inhibitors (FAPIs) suggest high potential for superior tumor detection. Here, we report the data of a large malignant pleural mesothelioma cohort within a 68Ga-FAPI46 PET observational trial (NCT04571086).
Methods
Of 43 eligible patients with suspected or proven malignant mesothelioma, 41 could be included in the data analysis of the 68Ga-FAPI46 PET observational trial. All patients underwent 68Ga-FAPI46 PET/CT, contrast-enhanced CT, and 18F-FDG PET/CT. The primary study endpoint was the association of 68Ga-FAPI46 PET uptake intensity and histopathologic FAP expression. Furthermore, secondary endpoints were detection rate and sensitivity, specificity, and positive and negative predictive values as compared with 18F-FDG PET/CT. Datasets were interpreted by 2 masked readers.
Results
The primary endpoint was met, and the association between 68Ga-FAPI46 SUVmax or SUVpeak and histopathologic FAP expression was significant (SUVmax: r = 0.49, P = 0.037; SUVpeak: r = 0.51, P = 0.030).68Ga-FAPI46 and 18F-FDG showed similar sensitivity by histopathologic validation on a per-patient (100.0% vs. 97.3%) and per region (98.0% vs. 95.9%) basis. Per-region analysis revealed higher 68Ga-FAPI46 than 18F-FDG specificity (81.1% vs. 36.8%) and positive predictive value (87.5% vs. 66.2%).
Conclusion
We confirm an association of 68Ga-FAPI46 uptake and histopathologic FAP expression in mesothelioma patients. Additionally, we report high sensitivity and superior specificity and positive predictive value for 68Ga-FAPI46 versus 18F-FDG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; lukas.kessler@uk-essen.de.
- Institute of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- German Cancer Consortium, Partner Site Essen, Essen, Germany.
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Zitieren
APA
Kessler, L., Schwaning, F., Metzenmacher, M., Pabst, K., Siveke, J., Trajkovic-Arsic, M., Schaarschmidt, B., Wiesweg, M., Aigner, C., Plönes, T., Darwiche, K., Bölükbas, S., Stuschke, M., Umutlu, L., Nader, M., Theegarten, D., Hamacher, R., Eberhardt, W. E. E., Schuler, M., …, & Hautzel, H. (2024). Fibroblast Activation Protein–Directed Imaging Outperforms 18 F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.267473
Vancouver
Kessler L, Schwaning F, Metzenmacher M, Pabst K, Siveke J, Trajkovic-Arsic M, et al. Fibroblast Activation Protein–Directed Imaging Outperforms 18 F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.267473
BibTeX
@article{Kessler2024,
author = {Kessler, Lukas and Schwaning, Felix and Metzenmacher, Martin and Pabst, Kim and Siveke, Jens and Trajkovic-Arsic, Marija and Schaarschmidt, Benedikt and Wiesweg, Marcel and Aigner, Clemens and Plönes, Till and Darwiche, Kaid and Bölükbas, Servet and Stuschke, Martin and Umutlu, Lale and Nader, Michael and Theegarten, Dirk and Hamacher, Rainer and Eberhardt, Wilfried E E and Schuler, Martin and Herrmann, Ken and Fendler, Wolfgang P and Hautzel, Hubertus},
title = {Fibroblast Activation Protein–Directed Imaging Outperforms 18 F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.124.267473}
}
EUVIMED